RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Dermapharm Holding Revenue 2024

Dermapharm Holding Revenue

1.16 B EUR

Dermapharm Holding Dividend yield

Ticker

DMP.DE

ISIN

DE000A2GS5D8

WKN

A2GS5D

In 2024, Dermapharm Holding's sales reached 1.16 B EUR, a 2.08% difference from the 1.14 B EUR sales recorded in the previous year.

The Dermapharm Holding Revenue history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)
2029e--
2028e--
2027e--
2026e--
2025e--
2024e--
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--

Dermapharm Holding Aktienanalyse

What does Dermapharm Holding do?

Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich. Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications. The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products. Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products. Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women. Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils. Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products. Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Dermapharm Holding's Sales Figures

The sales figures of Dermapharm Holding originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Dermapharm Holding’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Dermapharm Holding's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Dermapharm Holding’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Dermapharm Holding Stock

How much revenue did Dermapharm Holding generate this year?

Dermapharm Holding has achieved a revenue of 1.16 B EUR this year.

How much was the turnover of the company Dermapharm Holding compared to the previous year?

The revenue of Dermapharm Holding has increased by 2.08% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Dermapharm Holding?

The revenue of Dermapharm Holding is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Dermapharm Holding measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Dermapharm Holding so important for investors?

The revenue of Dermapharm Holding is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Dermapharm Holding pay?

Over the past 12 months, Dermapharm Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dermapharm Holding is expected to pay a dividend of 1.14 EUR.

What is the dividend yield of Dermapharm Holding?

The current dividend yield of Dermapharm Holding is .

When does Dermapharm Holding pay dividends?

Dermapharm Holding pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Dermapharm Holding?

Dermapharm Holding paid dividends every year for the past 0 years.

What is the dividend of Dermapharm Holding?

For the upcoming 12 months, dividends amounting to 1.14 EUR are expected. This corresponds to a dividend yield of 3.39 %.

In which sector is Dermapharm Holding located?

Dermapharm Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dermapharm Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dermapharm Holding from 7/2/2024 amounting to 0.88 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Dermapharm Holding pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Dermapharm Holding in the year 2023?

In the year 2023, Dermapharm Holding distributed 2.17 EUR as dividends.

In which currency does Dermapharm Holding pay out the dividend?

The dividends of Dermapharm Holding are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dermapharm Holding stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital

Andere Kennzahlen von Dermapharm Holding

Our stock analysis for Dermapharm Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dermapharm Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.